FBRX · NASDAQ · STOCK
Forte Biosciences (FBRX) Stock Analysis
$77.00
52W $10.11 – $77.20
57/100
$1.63B
-16.8
2.65
Is FBRX Bullish or Bearish?
Mixed.
Innellis AI committee rates Forte Biosciences, Inc. (FBRX) Watch with a composite score of 57/100
, based on 6 analysts with 50% agreement.
Last updated September 06, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +3.40 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -16.60 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.8% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price-to-book of 5.6x prices in significant intangible value — Value
- ROE of only -94.8% -- cheap may mean cheap for a reason — Value
- Revenue declining -99.8% YoY -- this is not a growth story right now — Growth
- 3 consecutive earnings misses -- execution concerns — Growth
- RSI at 85 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of September 06, 2026
Overall Committee Score
57/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 53%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 5.6x prices in significant intangible value
Growth Analyst
bearish
40
/ 100 · High confidence
Growth story is weak, decelerating, or inconsistent
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− Revenue declining -99.8% YoY -- this is not a growth story right now
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 85 is in overbought territory
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
48
/ 100 · Moderate confidence
News flow is mixed or quiet -- no strong signal either way right now
− No news coverage in the last 14 days -- limited independent confirmation either way
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2704.43)
Investment Thesis Evolution
Committee score moved marginally from 56.6 to 56.6.
Comparing 2026-09-05 to 2026-09-06 (1 day apart).
Technical Analysis
RSI (14)
85.0
Overbought
MACD Histogram
-1.747
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$76.75
Above
EMA 21
$72.78
Above
EMA 50
$58.87
Above
EMA 200
$35.44
Above
Fundamental Analysis
Valuation
67
Growth
53
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-16.8×
P/B Ratio
9.96×
PEG Ratio
-0.43
Dividend Yield
0.00%
52W High
$77.20
52W Low
$10.11
Quality & Growth
ROE
-11374.6%
ROA
-8380.8%
Gross Margin
0.0%
Operating Margin
0.0%
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
P/E ratio of -16.8 (inexpensive relative to a 15-40x range); Price-to-book of 10.0x; PEG ratio of -0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -113.7%; Return on assets of -83.8%; Net margin of 0.0%; Gross margin of 0.0%; Current ratio of 10.01 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-3.03); Most recent quarter missed estimates by 8.2%; 3 consecutive earnings misses; EPS growth accelerating (+10.8% -> +21.8% QoQ); Average YoY EPS growth of -1.0%; Analyst estimates rising over recent quarters
Get the Full FBRX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →